Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VNRX-5133 DDI and Safety Study
NCT03332732Phase 1Completed
- Sponsor
- Venatorx Pharmaceuticals
- Start
- Oct 2017
- Primary completion
- Dec 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of taniborbactam in bacterial infection (5 arms), sponsored by Venatorx Pharmaceuticals. Primary endpoints: Peak Plasma Concentration and Area Under the Curve. Started Oct 2017; status: completed.
02
Drugs
taniborbactam
03
Conditions
bacterial infection
Beyond the preview
Go deeper on NCT03332732.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03332732.